EPO and acute kidney injury: The administration of recombinant EPO in experimental models of AKI and renal transplant promoted tubular cell survival and tissue vascularization, resulting in improved renal function14, 15, 16, 17, 18, 19, 20, 21 and long term reduction of fibrosis22, 23.